FDA Investigator Susan W Ting

Susan W Ting has conducted inspections on 45 sites in 8 countries as of 26 Oct 2009. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
45
Last Inspection Date:
26 Oct 2009
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Japan, China, Turkey, Taiwan, United States of America, Singapore, Italy, Macao
FDA Investigators that have inspected at least one site in common with Susan W Ting:
Alice S Tsao, Alicia M Mozzachio, Angela E Glenn, Anh M Lac, Ann L Demarco, Anthony A Charity, Arsen Karapetyan, Atul J Agrawal, Azza Talaat, Barbara J Rincon, Bijoy Panicker, Bonita S Chester, Brandy N Lepage, Brenda W Uratani, PhD, Burnell M Henry, Candido Torres, Carl Lee, CDR Ileana Barreto Pettit, Charisse K Green, Charles I Ann, Charles M Edwards, Christina A Miller, Cynthia J Lee, MS, David R Delucia, Dell S Moller, Dennis Cantellops Paite, Devaughn Edwards, Donald L Lech, Dr. Chunchang Fang, Dr. Gang Wang, PhD, Dr. Guang Gao, PhD, Dr. Robert C Horan, MD, Elizabeth D Connell, Farhana Khan, Francis A Guidry, Gary J Lehr, Gary L Pierce, George J Flynn, Grace E Mcnally, Gwyn G Dickinson, Helen Verdel, Heriberto Negron Rivera, Hung H Do, MS, Irina Gaberman, Isabel Y Espinosa, Jacqueline S Warner, James A Liubicich, James C Maclaughlin, James M Mason, Javier O Vega, Jay T Wong, Jessica L Pressley, John D White, John M Dietrick, Jorge L Gonzalez, Jose A Lopez, Jose Ohernandez Guzman, Jose R Hernandez, Joshua P Wireman, Junho Pak, Justin A Boyd, Karen K Moksnes, Karen L Kosar, Karen Takahashi, Karyn M Campbell, Katherine Szestypalow, Kent C Faul, Kevin A Gonzalez, Kham Phommachanh, Khoa Nathanv Tran, Kristy A Zielny, Larry K Austin, Laurimer Kuilan Torres, Leonard H Lavi, Lindsey M Schwierjohann, Luis A Dasta, Marcellinus D Dordunoo, Marie F Morin, Marijo B Kambere, PhD, Matt D Suedkamp, Matthew B Casale, Matthew J Johnson, Michael A Charles, Michael A Taylor, Michael Levin, Michele L Obert, Minh D Phan, Mra Davism, Mra Munizn, Nasir Ali, PhD, Niketa Patel, Omadevi Somai, Investigator, Parul M Patel, Patty P Kaewussdangkul, Paul L Bellamy, Paula J Bretz, Peter E Baker, Qin Xu, Richard E Needham, Richmond K Yip, Robert C Steyert, Robert D Tollefsen, Rochelle K Kimmel, Rochelle L Cross, Rory K Geyer, Rowena S Nguyen, Roy R Rinc, Saied A Asbagh, Samantha J Bradley, Sandra A Hughes, Scott T Ballard, Shirley H Isbill, Sony Mathews, Sonya M Edmonds, Stacie A Woods, Stephen J Mottola, Steven D Kehoe, Steven P Donald, Susan F Laska, MS, Syed N Ali, Ted L Anderson, Temar Q Williams, Terri L Dodds, Thomas J Arista, Thomas J Mooney, Thomas S Savage, Timothy T Kapsala, Truong Xuan Nguyen (Andy), Uttaniti Limchumroon (Tom), William A Warnick, William J Leonard, Yasamin Ameri, Yumi J Hiramine, Yvette I Henry, Yvette I Johnson, Zachary A Bogorad, Zi Qiang Gu

Susan W Ting's Documents

Publish Date Document Type Title
June, 2001 EIR Zhejiang Kangle Pharmaceutical Co., Ltd. - EIR, 2001-06-02
July, 2000 FDA 483 Response Jerome Stevens Pharmaceuticals, Inc. - Form 483R, 2000-09-21
August, 2003 EIR Shimadzu Techno Research Inc. - EIR, 2003-10-08
September, 2000 FDA 483 Tianjin Xin Xin Pharmaceutical Corp. - Form 483, 2000-09-07
September, 2003 FDA 483 Sumika Fine Chemicals Co. - Form 483, 2003-09-04
November, 2004 FDA 483 Hovione Pharmascience Limited - Form 483, 2004-11-03
May, 2001 FDA 483 KAKEN Pharmaceutical Co., LTD - Form 483, 2001-05-18
May, 2001 EIR KAKEN Pharmaceutical Co., LTD - EIR, 2001-07-11
September, 2003 FDA 483 Response Sumitomo Chemical Company, Limited - Form 483R, 2003-09-30
August, 2003 FDA 483 Response Astellas Pharma Inc. - Form 483R, 2003-09-18
September, 2000 FDA 483 Response Tianjin Zhong Xin Pharmaceutical - Form 483R, 2000-10-27
May, 2001 EIR MSD International GmbH (Singapore Branch) - EIR, 2001-07-13
September, 2000 EIR Jiangsu Hengrui Medicine Co., Ltd. - EIR, 2000-10-19
October, 2003 FDA 483 Response Shanghai Medicinal Ltd. No. 15 Pharmaceutical Factory - Form 483R, 2003-11-10
October, 2003 EIR Shanghai Medicinal Ltd. No. 15 Pharmaceutical Factory - EIR, 2003-12-09
August, 2003 FDA 483 Nisshin Pharma Inc. - Form 483, 2003-08-29
September, 2000 FDA 483 Response Jiangsu Hengrui Medicine Co., Ltd. - Form 483R, 2000-11-06
July, 2000 EIR Jerome Stevens Pharmaceuticals, Inc. - EIR, 2000-07-26
August, 2003 FDA 483 Response Shimadzu Techno Research Inc. - Form 483R, 2003-10-21
August, 2003 EIR Astellas Pharma Inc. - EIR, 2003-10-08
July, 2000 FDA 483 Jerome Stevens Pharmaceuticals, Inc. - Form 483, 2000-07-26
October, 2003 FDA 483 Takeda Pharmaceutical Company Limited - Form 483, 2003-10-24
October, 2003 EIR Takeda Pharmaceutical Company Limited - EIR, 2003-12-18
March, 2006 EIR Chirogate International Inc. - EIR, 2006-03-22
June, 2001 FDA 483 Response Zhejiang Kangle Pharmaceutical Co., Ltd. - Form 483R, 2001-06-12
September, 2000 EIR Tianjin Zhong Xin Pharmaceutical - EIR, 2000-10-27
September, 2003 EIR Sumitomo Chemical Company, Limited - EIR, 2003-10-09
September, 2000 FDA 483 Jiangsu Heingrui Pharmaceuticals Co., LTD - Form 483, 2000-09-13
August, 2003 FDA 483 Astellas Pharma Inc. - Form 483, 2003-08-22
May, 2001 FDA 483 Response KAKEN Pharmaceutical Co., LTD - Form 483R, 2001-06-27
October, 2003 FDA 483 Shanghai Medicinal Ltd. No. 15 Pharmaceutical Factory - Form 483, 2003-10-31

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more